Prelude Therapeutics's market cap is currently $49.67M. The company's EPS TTM is $-1.901; its P/E ratio is ―; Prelude Therapeutics is scheduled to report earnings on March 12, 2025, and the estimated EPS forecast is $-0.47. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Gross Profit	$ -1.17M	$ -3.04M	$ -2.24M	$ -542.00K	$ -382.00K
Operating Income	$ -132.28M	$ -123.54M	$ -113.73M	$ -58.76M	$ -28.11M
EBITDA	$ -131.11M	$ -122.22M	$ -112.82M	$ -58.22M	$ -27.73M
Net Income	$ -121.83M	$ -107.34M	$ -110.78M	$ -56.93M	$ -27.57M
Balance Sheet
Cash & Short-Term Investments	$ 232.94M	$ 201.73M	$ 291.23M	$ 218.31M	$ 18.88M
Total Assets	$ 277.67M	$ 220.50M	$ 305.10M	$ 223.59M	$ 21.87M
Total Debt	$ 16.89M	$ 1.83M	$ 1.74M	$ 0.00	$ 258.00K
Net Debt	$ -8.40M	$ -28.77M	$ -30.09M	$ -218.31M	$ -18.62M
Total Liabilities	$ 40.58M	$ 25.06M	$ 19.20M	$ 11.41M	$ 71.28M
Stockholders' Equity	$ 237.09M	$ 195.44M	$ 285.90M	$ 212.18M	$ -49.41M
Cash Flow
Free Cash Flow	$ -110.58M	$ -86.75M	$ -85.85M	$ -46.80M	$ -26.45M
Operating Cash Flow	$ -107.06M	$ -83.73M	$ -83.53M	$ -46.18M	$ -25.66M
Investing Cash Flow	$ -34.65M	$ 81.69M	$ -263.80M	$ -621.00K	$ -780.00K
Financing Cash Flow	$ 136.40M	$ 815.00K	$ 164.90M	$ 246.23M	$ 29.73M

Currency in USD

Prelude Therapeutics Earnings and Revenue History

Income Statement >

Prelude Therapeutics Debt to Assets

Balance Sheet >

Prelude Therapeutics Cash Flow

Cash Flow >

Prelude Therapeutics Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing